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Summary
 
The immunoglobulin-like family of CD66 antigens, present on human neutrophils and epithe-
lial cells, are used as receptors for adhesins expressed by the pathogenic 
 
Neisseriae
 
. 
 
N
 
.
 
 gonorrhoeae
 
strain MS11 can express 11 isoforms of these adhesins, called opacity-related (Opa) proteins.
Each MS11 Opa protein recognizes a distinct spectrum of CD66 receptors. CD66–Opa bind-
ing is mediated by the NH
 
2
 
-terminal domain of the receptor and occurs through protein–protein
interactions. In this report, we have investigated the molecular basis for the binding between
the CD66 and Opa protein families by mapping amino acids in CD66 receptors that determine
Opa protein binding. We performed homologue scanning mutagenesis between CD66e,
which binds multiple Opa variants, and CD66b, which binds none, and tested both loss-of-
function by CD66e and gain-of-function by CD66b in solution assays and in assays involving
full-length receptors expressed by epithelial cells. We found that three residues in the CD66e
N-domain are required for maximal Opa protein receptor activity. Opa proteins that recognize
the same spectrum of native CD66 molecules showed differential binding of receptors with
submaximal activity, indicating that the binding characteristics of these Opa proteins are actually
slightly different. These data provide a first step toward resolving the structural requirements for
Opa–CD66 interaction.
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T
 
he causative agent of gonorrhea, 
 
Neisseria gonorrhoeae
 
(Ngo),
 
1
 
 is an obligate human bacterial pathogen. The
bacteria are thought to colonize the urogenital mucosa us-
ing different adhesins in a sequential manner. Initial attach-
ment is mediated by gonococcal pili. Subsequently, tighter
adherence to the mucosal epithelial cells is provided by bac-
terial adhesins called opacity-related (Opa) proteins (1, 2).
Both pathogenic 
 
Neisseria
 
 species, Ngo and 
 
Neisseria menin-
gitidis
 
 (Nme), contain multiple 
 
opa
 
 genes. The expression of
each
 
 opa
 
 gene can be turned on or off independently (phase
variation) through a process of slipped-strand mispairing
(3). Members of the Opa protein family are highly homolo-
gous, except for variable sequence domains present in three
of the four surface exposed loops (4). Opa proteins were
shown to account for the cell tropisms displayed by Ngo
for human neutrophils and epithelial cells (5). Two types of
Opa protein receptors have been identified. One is the
heparan-sulfate proteoglycan receptor (HSPG), present on
epithelial cells, which mediates binding and internalization of
one particular Opa variant of Ngo strain MS11 (OpaA [6, 7]).
The other receptor type include members of the carcino-
embryonic antigen (CEA) or CD66 family, present on neu-
trophils and epithelial cells; they are recognized by multiple
Opa variants of Ngo and Nme (8–11). The CD66 glycopro-
tein receptors belong to the Ig superfamily (IgSF): the mol-
ecules consist of one NH
 
2
 
-terminal Ig variable–like domain
(N-domain) plus a varying number of Ig constant–like do-
mains linked to the plasma membrane through a trans-
membrane domain or a glycosyl phosphatidylinositol moi-
ety (12, 13). The proteins were discovered decades ago when
certain family members (CD66e [CEA] and CD66c) were
found to be highly overexpressed in a large number of tu-
mors; CEA has since become the prototype tumor marker.
The function of CD66 glycoproteins in normal tissue or in
tumorigenesis is still unclear, although the demonstration
that these molecules function in vitro as cell adhesion mol-
ecules (CAMs) may indicate that they contribute to tissue
architecture or to other cell–cell interactions (14). Interest-
ingly, certain CD66 glycoproteins are subverted as recep-
tors for bacterial (
 
Escherichia coli
 
 or 
 
Salmonella
 
 expressing
type I pili [15]) or viral (murine coronaviruses [16]) patho-
 
gens; recently, the pathogenic 
 
Neisseriae 
 
have been added
 
1
 
Abbreviations used in this paper:
 
 CAM, cell adhesion molecule; CHO, Chinese
hamster ovary; CEA, carcinoembryonic antigen; GAM, goat anti–mouse;
 
GAR, goat anti–rabbit; ICAM, intercellular adhesion molecule; IgSF, im-
munoglobulin superfamily; mut, mutant; N-domain, NH
 
2
 
-terminal Ig
 
variable–like domain; Ngo, 
 
Neisseria gonorrhoeae
 
; Nme, 
 
Neisseria meningiti-
dis
 
; Opa, opacity-related. 
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to this list. To date, five members of the CD66 family
(CD66a–e) have been studied for their interaction with gono-
coccal Opa proteins. We and others have found that this in-
teraction is highly differential, i.e., some CD66 family mem-
bers are recognized by four Opa variants while other CD66
receptors are recognized by none (CD66b), six (CD66a), or
nine (CD66e) different Opa variants of Ngo strain MS11
(10, 11, 17). We recently showed that the differential inter-
action observed with native receptors expressed on epithelial
cells is mimicked by the binding pattern of recombinant
CD66 N-domains produced in 
 
E
 
.
 
 coli
 
 (18), indicating that
the Opa–CD66 interaction is mediated by protein sequences
in CD66 N-domains. It is remarkable that, despite exten-
sive sequence similarity among the CD66a–e N-domains
(71–90% amino acid sequence identity; see Fig. 1 A), the
N-domains are recognized by different groups of Opa pro-
teins. In our effort to understand the differential Opa–CD66
interactions, we investigated the molecular basis for the bind-
ing between the Opa and CD66 protein families. Homo-
logue scanning mutagenesis, a strategy chosen to preserve
structural integrity of mutant molecules (19), was used to
map key residues in CD66 required for Opa protein binding.
Residues within the N-domain of CD66e (which binds
most Opa variants) were switched to homologous amino ac-
ids of the N-domain of CD66b (which does not bind any
Opa variant). The key residues identified through loss-of-
function mutations were confirmed by gain-of-function ex-
periments, whereby the CD66b protein was converted into
a functional receptor for Opa variants.
 
Materials and Methods
 
Bacterial Strains. N
 
.
 
 gonorrhoeae
 
 MS11 variants were propa-
gated on gonococcal clear typing agar (20). Wild-type variants
MS11mk expressing chromosomally encoded Opa proteins were
provided by J. Swanson and are designated according to Swanson
et al. (21) by capitals, e.g., OpaA–OpaK. Recombinant MS11
Opa variants (5) were a gift of T.F. Meyer (Max-Planck Institut
für Biologie, Tübingen, Germany). Opa protein expression was
verified by SDS-PAGE and immunoblotting of bacterial lysates
followed by detection with anti-Opa antibody 4B12 (21). Only
nonpiliated bacteria were used. For experiments, bacteria were
grown for 3 h in 10 ml Hepes medium (10 mM Hepes, 145 mM
NaCl, 5 mM KCl, 0.5 mM MgCl
 
2
 
, 1 mM CaCl
 
2
 
, 5 mM glucose,
and 1.5% proteose peptone no. 3 [Difco]), pH 7.4, in a gyratory
shaker at 37
 
8
 
C. Bacterial suspensions were pelleted and resus-
pended in 1 ml Hepes buffer (Hepes medium without proteose
peptone).
 
Construction of Mutant CD66 N-domains.
 
The construction of
6xHis-tagged N-domains of CD66e and CD66b in the pRSET-A
vector was described previously (18). Mutations were introduced
in CD66 N-domains by a modification of the procedure of Pi-
card et al. (22). In brief, a mutagenic primer was designed con-
taining the desired base changes flanked by at least 12 perfectly
matched bases both upstream and downstream of the mutation (a
list of primers is available on request). A megaprimer was generated
by PCR using the mutagenic primer and a common vector-based
3
 
9
 
 primer (pRSET-rev) with the CD66 N-domain construct as
template. The pRSET-rev primer was removed by passing the
reaction mixture through a 100-kD Centricon device (5 min at
 
3,000 
 
g
 
; Amicon).
 
 
 
A second PCR was performed with the same
template plus 17 
 
m
 
l of the 50 
 
m
 
l of 100-kD Centricon retentate
as 3
 
9
 
 primer and a common vector-based 5
 
9
 
 primer (pRSET-for).
The resultant PCR product was cut with EcoRI and HindIII and
ligated into pRSET-A. Constructs were electroporated into 
 
E
 
.
 
 coli
 
strain BL21 (DE3; Novagen). Mutations were verified by DNA
sequencing through the entire N-domain insert. Primers were
purchased from Genosys and restriction enzymes from New En-
gland Biolabs.
 
Binding of CD66 N-domains by Gonococci.
 
Cleared lysates of
 
E
 
.
 
 coli
 
 cells expressing the appropriate CD66 N-domain were pre-
pared as described (18). Gonococci (10
 
8
 
) in 200 
 
m
 
l Hepes buffer
were incubated with 5–10 
 
m
 
l of cleared lysate for 20 min at 37
 
8
 
C.
Bacteria were collected by centrifugation (5 min at 2,000 
 
g
 
),
washed twice with 1 ml Hepes buffer, then solubilized in 30 
 
m
 
l
SDS-PAGE sample buffer of which 2.5 
 
m
 
l was electrophoresed in
13.5% SDS-PAGE and transferred onto nitrocellulose. Bound
CD66 N-domains were detected by anti-His antibody (1:15,000;
Amersham Pharmacia Biotech) followed by peroxidase-conju-
gated protein A (1:20,000; Sigma Chemical Co.). Blots were de-
veloped using the enhanced chemiluminescence (ECL) protocol
(Amersham Pharmacia Biotech). Documentation and quantifica-
tion of bands were performed with an AlphaImager
 
®
 
 2000 Imag-
ing system (Alpha Innotech).
 
Construction of CD66b cDNA Mutants.
 
CD66b cDNA in
pUC118 was a gift from Motomu Kuroki (Fukuoka University,
Fukuoka, Japan). The CD66b insert was subcloned into the eu-
karyotic expression vector pTracer-CMV2 (Invitrogen). All mu-
tations were made first in the CD66b N-domain construct in
pRSET-A as outlined above. To introduce mutated N-domains
into the full-length CD66b cDNA, the BlpI site present at the
start of the N-domain in CD66b cDNA was introduced in the
CD66b N-domain construct in the pRSET-A vector by PCR.
For introduction of the chimeric CD66e/b N-domain into
CD66b, the BlpI site present in CD66b (GCTCAGC) was mu-
tated to the BlpI site found in CD66e (GCTAAGC) by mega-
primer PCR, in order to have the N-domain start with the
CD66e-derived lysine. The resultant PCR product was cleaved
with BlpI and NsiI (NsiI cuts at residue 71 in CD66 N-domains)
and substituted with the fragment present in the full-length CD66b
cDNA in pTracer-CMV2. To substitute the entire CD66b
N-domain with the CD66e N-domain, a silent mutation con-
taining a ClaI site was introduced at residue 113 just downstream of
the N-domain in CD66b. The CD66e N-domain in pRSET-A was
amplified with primers containing a BlpI and a ClaI site, respectively,
cut and ligated into BlpI/ClaI-cut CD66b. The constructs were
electroporated into 
 
E
 
.
 
 coli
 
 DH5
 
a
 
.
 
 All mutations in the pTracer-
CMV2-CD66b constructs were verified by DNA sequencing.
 
Transfection Procedure.
 
Chinese hamster ovary (CHO) cells
(Pro5) were obtained from the American Type Culture Collec-
tion and were grown in RPMI 1640/5% FCS in 25-cm
 
2
 
 flasks to
50% confluency. Plasmid preparations of pTracer-CMV2-CD66b
mutants were made by the Wizard miniprep procedure (Promega
Corp.). Pro5 cells were incubated in 2 ml DMEM/10% Nu-
serum (Collaborative Biomedical Products) containing 4 
 
m
 
g plas-
mid DNA and 0.2 mg/ml DEAE-dextran (
 
M
 
r
 
 5 
 
3 
 
10
 
5
 
; Amer-
sham Pharmacia Biotech) for 4 h at 37
 
8
 
C. Cells were then
shocked with 2.5 ml 10% DMSO in PBS for 1 min at room tem-
perature, washed once with HBSS, and subsequently cultured
overnight in RPMI 1640/5% FCS (23). The next day, the trans-
fectants were trypsinized and seeded onto 12-mm-diameter cir-
cular glass coverslips in 24-well plates (10
 
5
 
 cells per coverslip). Cells
were cultured for 2–3 d before infection assays were carried out. 
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Infection Assay.
 
Gonococci (1.5 
 
3 
 
10
 
7
 
) were added to 24-well
plates containing the transfected cell cultures on coverslips, in 1 ml
DMEM (without serum) for 45 min at 37
 
8
 
C and 5% CO
 
2
 
. Non-
adherent bacteria were removed by three washes with HBSS. In-
fected cultures were fixed with 2% formaldehyde in PBS for at
least 30 min.
 
Staining Procedures.
 
Fixed infected cells were incubated with
0.5% Triton X-100 in PBS for 20 min and then blocked with 5%
FCS in PBS for 1 h. Antibodies were diluted in PBS/0.05%
Tween/0.5% FCS. To detect receptor expression, cells were
stained with rabbit anti-CD66 antiserum (1:200; Dako) followed
by Alexa 594–conjugated goat anti–rabbit (GAR) IgG (1:400;
Molecular Probes, Inc.). To subsequently stain gonococci, cover-
slips were incubated with a mouse mAb against gonococcal LPS,
generated in our laboratory by J. Swanson, followed by FITC-
conjugated goat anti–mouse (GAM) IgG (1:400; Sigma Chemical
Co.). When only receptor expression was evaluated, the perme-
abilization step with Triton X-100 was omitted. mAb Kat4C was
provided by H. Turley (John Radcliffe Hospital, Oxford, UK).
To distinguish extra- and intracellular bacteria, infected cell cul-
tures on coverslips were subjected to a differential staining proce-
dure as described previously (10, 24). In brief, fixed cells were in-
cubated successively with an anti-LPS mAb and a protein A–gold
conjugate. The gold was enhanced by silver-staining to visualize
extracellular bacteria, after which cells and intracellular bacteria
were stained with 0.005% crystalviolet in H
 
2
 
O for 10 min.
 
Results
 
Identification of CD66e N-domain Residues Critical for Bind-
ing of Opa-expressing Gonococci.
 
The differential recognition
of CD66 receptor N-domains by gonococcal Opa variants
is shown in Table I. CD66e is recognized by the majority
of Opa variants, whereas CD66b does not bind any Opa
variant. OpaB, OpaC, OpaG, and OpaI variants demon-
strate the broadest recognition of CD66 receptors. Assays
with previously constructed chimeric receptor N-domains
consisting of the NH
 
2
 
-terminal half (residues 1–59) of
CD66e fused to the COOH-terminal half of the CD66b
N-domain and vice versa, located the critical domain for
binding of OpaB, OpaC, OpaG, and OpaI variants to the
first 59 residues of CD66e (18; compare binding of the chi-
meric N-domains CD66e/b and CD66b/e in Table I). Us-
ing homologue scanning mutagenesis, we exchanged re-
gions and single residues between the NH
 
2
 
-terminal 59
residues of CD66e and CD66b (for sequence differences,
see Fig. 1 A) and measured the ability of the mutant proteins
to bind to Opa
 
2
 
, OpaB-, OpaC-, and OpaI-expressing
gonococci in order to identify CD66 residues required for
Opa protein binding. Since OpaG is nearly identical to
OpaB (25), we did not include this Opa variant in our assays.
As is shown in Table II and Fig. 2 A, mutations in the
first 11 residues of the CD66e N-domain did not influence
binding of any tested Opa variant. Mutation of the region
comprising residues 27–29 (mut3) resulted in a complete
loss of recognition by all variants. Evaluation of the indi-
vidual residues in this region revealed that the loss of bind-
ing was caused by the single F29R mutation (mut6). The
single mutation S32N (mut7) also abrogated all Opa bind-
ing. The double mutation G41A
 
1
 
Q44R (mut9) clearly di-
minished Opa binding, but when these mutations were
tested individually, a difference between Opa variants was
noted. For OpaI interaction, both the G41A and the
Q44R mutations were deleterious. This was also the case
for interaction with OpaC, although to a lesser extent. The
Q44R mutation had a moderate effect on OpaB binding,
whereas the G41A change had no effect at all. Mutations in
the region between residues 51 and 55 caused only a mod-
erate decrease in Opa binding. Thus, the two residues F29
and S32 in CD66e are critical for binding of all Opa vari-
ants, whereas residues G41 and Q44 are important to dif-
ferent extents for the various Opa proteins.
 
Gain-of-function by the non-Opa Binding CD66 Family
Member CD66b.
 
If the four residues indicated above were
indeed responsible for the receptor function of CD66e, it
should be possible to impart Opa binding properties to
CD66b by introducing those four residues into CD66b. To
test this concept, we changed the residues in question in
the CD66b N-domain to the corresponding ones of CD66e
in different combinations. As can be seen in Table III, the
presence of F29
 
1
 
S32 (mut13) did not result in detectable
binding of any Opa variant. Residue F29 in mut13 is pre-
ceded by two CD66b-specific residues, D27 and P28,
which may influence the correct conformation of F29. To
address whether the F29 residue in a more “CD66e-like”
environment would mediate Opa binding, we added resi-
dues H27 and L28 to mut13. This molecule (mut14) also
failed to bind significantly to any Opa variant. The A41G
 
1
 
R44Q mutant (mut15) did not bind any Opa variant either.
We then added the G41 and Q44 residues individually to
mut14, resulting in mut16 and mut17, and found that each
addition slightly enhanced binding of all Opa variants com-
pared with mut14. Only when both G41 and Q44 were
present (mut18) was full binding activity by all Opa variants
 
Table I.
 
Recognition of CD66 Receptor N-domains by MS11 
Opa Variants
 
Receptor
type
Opa variant
 
2
 
ABCDEFGHI JK
CD66e
 
221111111112
 
CD66a
 
221122111122
 
CD66c
 
221122212122
 
CD66d
 
221122212122
 
CD66b
 
222222222222
 
CD66b/e
 
222222222222
 
CD66e/b
 
221122212122
 
MS11 Opa variants were incubated with 
 
E. coli
 
 lysates containing the in-
dicated His-tagged CD66 N-domain and processed for immunoblotting.
Blots were probed with anti-His antibody and peroxidase-conjugated
protein A followed by ECL. When a significant signal was present on
the blot, recognition was defined as 
 
1
 
. CD66a–e are native N-domain
sequences; CD66b/e and CD66e/b represent chimeric N-domains be-
tween CD66b and CD66e, as described in reference 18. Some of these
data were shown previously in reference 18. 
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evident (Fig. 2 B). We then readdressed the question
whether the origin of residues 27 and 28 played any role in
Opa binding by construction of mut19–21. The presence
of F29
 
1
 
S32
 
1
 
G41
 
1
 
Q44 was sufficient for binding of OpaB
and OpaI variants; however, for OpaC binding an addi-
tional CD66e-derived residue (L28) was necessary, indicat-
ing a difference in binding characteristics among Opa vari-
ants (Fig. 2 B, and Table III). These data confirm the key
role of four residues in the CD66e N-domain for receptor
function of CD66e and again show a difference in binding
characteristics within the OpaB, OpaC, and OpaI group of
variants.
 
Expression and Recognition of Full-length CD66b Mutants on
the Surface of Epithelial Cells.
 
To confirm that these results
obtained with soluble recombinant His-tagged N-domains
reflect interactions taking place at the cell surface, we intro-
duced the identified key residues into full-length CD66b
cDNA, transfected CHO cells with these constructs, and
performed infection assays to determine Opa receptor ac-
tivity. All transfectants stained positive with mAb Kat4C,
which recognizes an epitope in internal CD66 domains (26;
data not shown), as well as with a polyclonal anti-CD66 se-
rum (Fig. 3), indicating that the receptors were expressed at
the surface of the cells.
Infection of the various transfectants with MS11 Opa
variants was evaluated by double immunofluorescence stain-
ing. Bacteria were found only on receptor-positive cells,
which comprised 50–75% of the total cell population. The
results of these experiments are shown in Table IV, with
Fig. 3 illustrating the designations used in Table IV. Sur-
prisingly, a single mutation in CD66b (N32S) resulted in
significant binding of OpaB (Fig. 3 c) and OpaI variants,
Figure 1. Protein sequence comparisons of CD66 N-domains. (A) Amino acid
alignment of CD66 N-domains, deduced from DNA sequencing of N-domain
clones as used in this and our previous study (reference 18). Dots indicate residues
identical to CD66e. (B) Diagrammatic figure of the fold of the CD66e domain as
predicted by Bates et al. (reference 32) and the PredictProtein computer program
(reference 33). Strand designation is indicated by capitals below the diagram.
Residues determining Opa protein binding as identified in this study are indi-
cated by circles.
 
Table II.
 
Binding of CD66e N-domain Mutants to MS11
Opa Variants
 
mut
Mutations introduced in the
CD66e N-domain
Binding by Opa variants
OpaB OpaC OpaI
None
 
11 11 11
 
1 K1Q
 
11 11 11
 
2 S6A
 
1
 
T7V
 
1
 
F9S
 
1
 
V11A
 
11 11 11
 
3 H27D
 
1
 
L28P
 
1
 
F29R
 
222
 
4 H27D
 
11 11 11
 
5 L28P
 
11 11 11
 
6 F29R
 
222
 
7 S32N
 
222
 
8 R38T
 
11 11 11
 
9 G41A
 
1
 
Q44R
 
1
 
/
 
22 2
 
10 G41A
 
11 1 2
11 Q44R 11 /21 /2
12 G51S1T52N1A55I 111
MS11 Opa variants were incubated with E. coli lysates containing the
indicated mutant (mut) CD66e N-domain and processed for immuno-
blotting. Binding was calculated by determining the signal generated by
the amount of His-tagged N-domain for each variant, compared with the
signal generated in a lane where an amount of His-tagged N-domain was
loaded representing 100% binding. Opa2 variants did not bind any
N-domain construct (data not shown). Results represent the mean of
two to four independent experiments. 11, .50% binding; 1, 20–50%
binding; 1/2, 5–20% binding; 2, ,5% binding.335 Bos et al.
but not of OpaC variants. The single mutations A41G and
R29F resulted in low level binding of OpaB (Fig. 3 b) and
OpaI variants, but not of OpaC variants. The single muta-
tion R44Q conferred no detectable Opa binding properties
upon CD66b. In addition, the double mutant R44Q1
N32S was indistinguishable from the N32S mutant, indi-
cating that the R44Q mutation did not contribute to Opa
binding. The double mutations R29F1N32S and N32S1
A41G resulted in binding of large numbers of OpaB, OpaC,
and OpaI variants (Table IV, and Fig. 3 d). Addition of
mutation P28L to N32S, to R29F1N32S, or to N32S1
A41G did not affect interaction with any Opa variant (data
not shown). The triple mutant R29F1N32S1A41G showed
strong binding of Opa variants: infections with OpaB and
OpaI variants resulted in distinct redistribution of the re-
ceptors towards the sites of bacterial adhesion, resulting
in footprint-like appearances in the microscope (Fig. 3 e).
This phenomenon was not seen with OpaC variants. The
triple mutant was indistinguishable from a CD66b receptor
containing the chimeric CD66e/b or the native CD66e
N-domain, indicating that maximal binding was achieved
with the triple mutant (Table IV). Opa2 variants did not
interact with any transfectant (data not shown). To deter-
mine whether the transfectants that bound Opa variants
were also able to ingest them, we applied a differential
staining procedure after infection of the cells. We found
that in all transfectants that bound Opa variants, intracellu-
lar gonococci could readily be found (Fig. 3 f). This dem-
onstrates that CD66b molecules, containing the appropri-
ate Opa binding domain, can act as complete functional
receptors for gonococcal Opa variants. In summary, our
findings show that, when introduced in full-length recep-
tors in CHO cells, the mutations R29F, N32S, and G41A
each conferred significant receptor activity upon CD66b,
with N32S being the most effective single mutation. Re-
placement of all three residues provided maximal adher-
ence of Opa variants. These gain-of-function experiments
largely confirm the results obtained with soluble receptor
N-domains, although the requirements for binding appear
to be less stringent. Furthermore, again using full-length
Figure 2. Binding of His-tagged mutant CD66 N-domains to MS11 Opa
variants. Shown are representative immunoblots of lysates derived from bac-
teria that had been incubated with His-tagged CD66 N-domain mutants.
The upper blot in A was probed with anti-His and anti-Opa antibody; other
blots with anti-His antibody only. Position of Opa proteins is indicated on
the right (Opa). Molecular mass standards (in kD) are indicated on the left of
the top panel in A. Lanes labeled lys indicate E. coli lysate, containing the ap-
propriate N-domain in an amount that would be seen on the blot if 100% of
the N-domain present in the lysate was bound by the gonococci. Lanes la-
beled –, B, C, and I indicate amount of N-domain bound by Opa2, OpaB-,
OpaC-, or OpaI-expressing gonococci, respectively.
Table III. Binding of CD66b N-domain Mutants by MS11 Opa Variants
mut
Mutations introduced in the N-domain
of CD66b
Binding by Opa variants
OpaB OpaC OpaI
None 222
13 R29F1N32S 222
14 D27H1P28L1R29F1N32S 222
15 A41G1R44Q 222
16 D27H1P28L1R29F1N32S1A41G 1/21 /21 /2
17 D27H1P28L1R29F1N32S 1R44Q 1/21 /21 /2
18 D27H1P28L1R29F1N32S1A41G1R44Q 11 11 11
19 R29F1N32S1A41G1R44Q 11 2 1
20 P28L1R29F1N32S1A41G1R44Q 11 11 11
21 D27H 1R29F1N32S1A41G1R44Q 11 2 11
MS11 Opa variants were incubated with E. coli lysates containing the indicated mutant (mut) CD66b N-domain and processed for immunoblotting.
Binding was calculated by determining the signal generated by the amount of His-tagged N-domain present for each variant, compared with the sig-
nal generated in a lane where an amount of His-tagged N-domain was loaded representing 100% binding. Opa2 variants did not bind any N-domain
construct (data not shown). Results represent the mean of two to four independent experiments. 11, .50% binding; 1, 20–50% binding; 1/2, 5–20%
binding; 2, ,5% binding.336 CD66 Receptor Residues Required for Opa Protein Binding
receptor mutants a difference in binding characteristics was
noted for variants expressing OpaC compared with OpaB
and OpaI variants.
Discussion
In this study, we have mapped residues on CD66 recep-
tors that determine Opa protein binding. We have identi-
fied three key amino acid residues in CD66e required for
maximal binding using homologue scanning mutagenesis
and subsequent analysis of both loss-of-function and gain-
of-function of CD66 mutants in binding and infection as-
says. Furthermore, Opa proteins B, C, and I, which bind to
an identical spectrum of native CD66 receptors, were found
to differ in their recognition of mutant CD66 N-domains
and mutant receptors on cells, indicating that their binding
characteristics may actually not be identical.
Neisserial Opa proteins are thought to span the bacterial
outer membrane in an eight-stranded b-barrel conforma-
tion resulting in four extracellular loops. Three of the ex-
posed loops consist of variable sequence domains while a
fourth loop near the COOH terminus of the protein is
highly conserved. The differential binding of Opa proteins
to CD66 receptors is likely a reflection of the ability of
these variable domains to interact with the receptors. As we
pointed out previously (10), it is remarkable that Opa pro-
teins, such as OpaB, OpaC, and OpaI, that contain heterol-
ogous variable domains recognize the same subgroup of
CD66 family members. However, our present data show-
ing differences in binding of mutant molecules by these
Opa proteins may indicate that they actually bind with
slightly different characteristics, which would be expected
from proteins with such divergent binding domain sequences.
The opa gene family is thought to have arisen from recent
gene duplication events and genetic reassortment of vari-
able sequence domains between members of the gene fam-
ily (25, 27–29). Interestingly, the CD66 family also appears
to have arisen recently by duplication of at least one ances-
tral gene. Sequence comparisons between the rodent and
primate CD66 gene families show higher interspecies than
intraspecies variation, suggesting that the duplication oc-
curred after mammalian radiation took place (30, 31). In
addition, the mutation rate in the CD66 N-domain exons
is twice as high as that of the adjacent intron, suggesting
Figure 3. Photomicrographs
of CHO cells transfected with
different mutant CD66b recep-
tors that were infected with
OpaB-expressing gonococci for
45 min (a–e) or 90 min (f). The
mutations introduced into
CD66b are indicated next to the
panels. (a–e) Permeabilized cells
were stained for receptor expres-
sion with anti-CD66 antiserum
plus GAR–Alexa 594 (red; a–e)
and subsequently with an anti-
LPS antibody plus GAM-FITC
(green) to visualize bacteria
(a–d). Images were obtained by
one exposure through a double
FITC/Texas Red bandpass opti-
cal filter using a 403 objective
(a–d) or through a Texas Red
bandpass filter using a 1003 ob-
jective (e). Note the increase in
number of associated bacteria
(green) with the introduction of
different CD66e residues into
CD66b (a–d). At maximal inter-
action, receptor redistribution
towards the sites of bacterial
adhesion becomes apparent as
footprint-like appearances (ar-
rows in e). (f) Light micrograph
of infected cells showing entry
of OpaB-expressing gonococci
into CHO cells expressing
CD66b1N32S. Extracellular
bacteria cells were visualized
with an anti-LPS antibody fol-
lowed by immunogold silver
staining and can be distin-
guished by the dark rim of sil-
ver/gold precipitate covering the diplococci (arrowhead). Intracellular bacteria were stained with crystalviolet and are discerned by lack of a black outline
and by their location in vacuolated intracellular compartments appearing as clear zones around the diplococci (arrow).337 Bos et al.
that the CD66 family is still undergoing rapid evolution (30).
It is tempting to speculate that the extensive evolution of the
opa gene family in the strictly human pathogen Ngo has taken
place in response to the rapidly evolving family of primate-
specific CD66 molecules. The observed differential Opa–
CD66 binding patterns may be a reflection of this process.
According to the predicted structure of the CD66e
N-domain (32), the residues we have identified as important
for Opa protein binding, F29, S32, and G41, are located in
exposed loops and strands of the GFCC9C99 face of the
CD66e N-domain (Fig. 1 B). This face of the molecule is
not covered by carbohydrate, in contrast to the ABED
face, as predicted by a low resolution model for CD66e
(34), and would therefore be accessible for protein–protein
interactions. The key role of S32 and G41 in binding of
Opa proteins is supported by the fact that these residues are
conserved among Opa-binding CD66 molecules (Fig. 1 A).
Residue F29 is conserved in three out of four of the Opa-
binding CD66 molecules (CD66a, d, and e), whereas CD66c
contains an I at residue 29. Possibly hydrophobic residues
such as F or I at that position support Opa protein binding,
while a charged residue, such as R present in CD66b, does
not. The role of residues L28 and Q44 is probably minor,
since they are not required for Opa recognition of the na-
tive molecule, although their presence enhances binding of
the soluble N-domain. Several ligand and viral binding sites
on IgSF members have been found on the GFC face of the
ligand-binding domain (35, 36), indicating that this domain
face is positioned favorably to serve as a ligand-binding
platform for IgSF members.
Homologue scanning mutagenesis does not address the
role of conserved residues among the two homologous pro-
teins in ligand binding. The finding that single, relatively
conservative mutations in CD66b, such as N32S and A41G,
were sufficient to induce receptor function in CD66b may
suggest that CD66b contains conserved residues participat-
ing in Opa protein binding. To test whether the actual
binding site is comprised in the first 59 residues of CD66e,
we constructed a truncated, His-tagged CD66e molecule
(residues 1–59) and tested it for binding to Opa variants.
This molecule was well expressed by E. coli but failed to bind
significantly to any Opa variant (data not shown), indicating
that other sites within the N-domain may be required for
binding or that the peptide did not adopt the correct confor-
mation for binding activity. The finding that single muta-
tions in CD66b result in functional receptor activity could
suggest that in vivo isoforms of CD66b exist that will be rec-
ognized by Opa variants. Evidence to support this concept
comes from analysis of CD66b cDNAs cloned from normal
white blood cells and leukemic cells. These cDNAs differed
in two base pairs in the coding region, resulting in two
amino acid differences, one in the N-domain (R80K) and
one in the COOH-terminal M-domain (V288L) (37, 38).
Cloning of another CD66 family member, CD66d, by two
different groups resulted in proteins differing in two resi-
dues (39, 40). These phenomena fit with the notion that
CD66 molecules are subject to sequence variation associ-
ated with rapid evolution.
CD66 family members are capable of mediating homo-
philic and heterophilic intercellular adhesion, like many
other IgSF proteins (41). Binding between CAMs is usually
of very low affinity, but due to the highly multimeric na-
ture of cell–cell adhesion, sufficient avidity can be achieved
to allow detection of the interaction between cells. The
weakness of CAM interactions is illustrated by the difficul-
ties in detecting binding of purified, monomeric forms of
CAMs. This difficulty arises because binding assays require
separation and washing steps, during which time weakly in-
teracting molecules dissociate (42). This phenomenon may
explain our observation that binding of Opa variants to sol-
uble CD66b N-domain mutants required more CD66e-
derived residues than binding to cell surface CD66 recep-
tors. If each mutation introduced into CD66b enhances
binding affinity between Opa and CD66b, as suggested by
our infection assay data, then the threshold level of affinity
necessary for detection will be reached sooner for the in-
fection assay than for binding in solution. Alternatively, the
level of multimerization may be important for Opa–CD66
binding, as has been shown for the binding of IgSF member
intercellular adhesion molecule 1 (ICAM-1) to its receptor
LFA-1. Recombinant ICAM-1 exists as monomers in so-
Table IV. Recognition by Opa Variants of Mutant Full-length 
CD66b Receptors Expressed by CHO Cells
Transfectant
Recognition by Opa variants
OpaB OpaC OpaI
CD66b 222
R29F 1/221 /2
N32S 121
A41G 1/221 /2
R44Q 222
N32S1R29F 11 1 11
N32S1A41G 11 1 11
N32S1R44Q 121
RF29F1N32S1A41G 11/fp 11 11/fp
CD66e/b 11/fp 11 11/fp
CD66e 11/fp 11 11/fp
Interaction with Opa variants was determined by evaluating the per-
centage of receptor-positive cells that had significant amounts of associ-
ated gonococci (.5 bacteria per cell). Presence of receptor and bacteria
was determined by immunofluorescence microscopy. The first column
indicates the mutations made in CD66b; CD66e/b and CD66e indi-
cate that the entire CD66b N-domain was replaced with either the chi-
meric N-domain mentioned in Table I or the entire native CD66e
N-domain. The results were tabulated as follows: 11/fp, all receptor-
positive cells were infected plus numerous footprints were present;
11, 60–90% of receptor-positive cells were infected; 1, 30–60% of
receptor-positive cells were infected; 1/2, 10–30% of receptor-posi-
tive cells were infected; 2, no infected cells present. Infection experi-
ments with recombinant MS11 Opa variants (reference 5) resulted in
identical recognition patterns as those shown here for wild-type MS11
Opa variants. Results represent the mean of two to four independent
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lution, and direct binding to LFA-1 has been impossible to
detect. Only when ICAM-1 was modified to induce
dimerization could LFA-1 binding be detected (43, 44).
CD66 family members can exist as dimers in the plasma
membrane of eukaryotic cells (45), and recombinant CD66e
N-domains have been shown to form oligomers in solution
(46). Receptor dimers will more likely be found on the
surface of cells, where the receptor concentration is higher
than in solution. Thus, if Opa binding requires a receptor
dimer, one would expect Opa variants to bind more readily
to receptor-expressing cells than to soluble receptors. An-
other possible explanation for the discrepancy between the
two binding detection methods is that in the solution assay
the receptor binding domain exists as an unglycosylated,
single domain, while in the infection assay the binding do-
main is presented in the context of a complete, glycosylated
molecule. Although Opa binding does not require carbo-
hydrate (18), the presence of sugar moieties may influence
the strength of adhesion, as has been observed for the inter-
action between CD2 and CD58. Human CD2 has a single
carbohydrate addition site in its Ig variable–like N-domain
that is absolutely required for binding to its normal ligand,
CD58. Evidence from solution structure of this carbohy-
drate chain in relation to the GFC binding face indicates
that the glycan is not itself situated in the binding face but is
required to balance an unfavorable negative charge in order
to maintain an active binding configuration (47). In fact,
CD66 N-domains contain a potential glycosylation site at
residue 70 (Fig. 1), which corresponds exactly to the struc-
tural position of the glycosylation site affecting ligand bind-
ing ability of human CD2 (41). Mutation of this site in
CD66e influences CD66e homophilic interactions, which
are based on protein–protein interactions, indicating that in
CD66e also the degree of glycosylation can influence bind-
ing events mediated through CD66 protein sequences (41).
Our data stress the importance of evaluating binding events
in different assays, since differences between assays can re-
veal further details of the molecular interaction between
ligands. Regardless of the molecular basis for the observed
discrepancy, both assays show clearly that OpaC binding
requires more CD66e-derived residues than OpaB or
OpaI, which may indicate that OpaC binding of the recep-
tor is of lower affinity than binding of OpaB or OpaI.
In conclusion, mapping of key residues in CD66 required
for recognition by the various gonococcal Opa adhesins in-
dicates that single amino acid residues in CD66 receptors
determine Opa protein binding. These results may provide
a first step towards resolving the structural requirements for
the Opa–CD66 receptor interaction and thereby help the
development of infection inhibitory strategies, and may
provide insights into the function of CD66 molecules in
normal tissue and in carcinogenesis.
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